Physician profile
Eumar T Tagupa
NPI 1497717128
$3,368.17
in general payments reported to CMS, 2019-2025
26 companies · $36.39 in 2025
The $36.39 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $411 · 2021: $1,039 · 2022: $1,000 · 2023: $410 · 2024: $37.15 · 2025: $36.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $483.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $552.24 | 2021-2024 | Onyx Frontier, Symplicity G3, Azure Xt Dr Mri Surescan |
| Janssen Pharmaceuticals, INC | $402.32 | 2020-2022 | |
| Pfizer INC. | $384.44 | 2019-2023 | |
| Medtronic Vascular, INC. | $324.47 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $315.30 | 2019-2023 | |
| Abbott Laboratories | $275.22 | 2019-2023 | Assurity, Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.41 | 2020-2023 | Jardiance |
| Amgen INC. | $180.51 | 2019-2023 | Repatha |
| Daxor Corporation | $165.07 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $56.91 | 2022-2023 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.65 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $49.78 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $44.87 | 2022-2023 | Verquvo |
| Inspire Medical Systems, INC. | $44.48 | 2023 | Inspire |
| Cvrx, INC. | $44.20 | 2022-2023 | Barostim Neo System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $41.96 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $39.85 | 2021-2022 | |
| Biosense Webster, INC. | $36.39 | 2025 | Carto 3 |
| Alnylam Pharmaceuticals INC. | $32.97 | 2022-2023 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $20.10 | 2019 | |
| Esperion Therapeutics, INC. | $16.83 | 2022 | |
| Novo Nordisk INC | $15.36 | 2023 | Ozempic, Rybelsus |
| Cook Medical LLC | $14.22 | 2019 | |
| Boston Scientific Corporation | $13.00 | 2020 | |
| Amarin Pharma, INC. | $12.20 | 2021 | |
| Cardiovascular Systems INC. | $5.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eumar Tagupa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.